Scarica l'app Stockscreener
24.15
5.85%
-1.50
Pre-mercato:
24.26
0.11
+0.46%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$25.65
Aprire:
$24.46
Volume 24 ore:
4.16M
Relative Volume:
1.02
Capitalizzazione di mercato:
$3.29B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-25.97
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
-17.52%
1M Prestazione:
-16.35%
6M Prestazione:
-61.85%
1 anno Prestazione:
-70.55%
Intervallo 1D:
$23.27
$24.50
Intervallo di 1 settimana:
$23.27
$29.56
Portata 52W:
$23.27
$82.00
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
24.15 | 3.29B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics stock hits 52-week low at $24.03 By Investing.com - Investing.com Australia
Viking Therapeutics stock hits 52-week low at $24.03 - Investing.com India
Viking Therapeutics (NasdaqCM:VKTX) Seals Manufacturing Deal as Stock Declines 11% Over The Past Month - Yahoo Finance
Which Healthcare Stock Is the Best Buy Right Now? - MarketBeat
A Closer Look at Viking Therapeutics's Options Market Dynamics - Benzinga
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet - Yahoo Finance
VKTX Finishes Enrolment in Mid-Stage Study on Oral Weight-Loss Drug - Yahoo Finance
Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study - Investor's Business Daily
Health Care Down as Viking Slides -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Completes Enrollment for Phase 2 Trial of Oral Obesity Tablet - Patient Care Online
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity - Marketscreener.com
Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity – Company Announcement - Financial Times
Better Stock to Buy Right Now: Viking Therapeutics vs. Eli Lilly - MSN
Viking Therapeutics, Inc. (VKTX) Rises But Trails Market: What Investors Should Know - MSN
(VKTX) Investment Analysis - Stock Traders Daily
Market Whales and Their Recent Bets on VKTX Options - Benzinga
1 Biotech Stock Down 52% That Could Soar by 233%, According to Wall Street - Yahoo Finance
Down 65% From Its 52-Week High, Is Viking Therapeutics Stock a Bargain Buy? - Nasdaq
Why Novo Nordisk Stock Outpaced the Market on Tuesday - The Motley Fool
Is Viking Therapeutics the Next Blockbuster GLP-1 Stock? - MarketBeat
Viking Therapeutics (NasdaqCM:VKTX) Soars 10% With CordenPharma Manufacturing Agreement - Yahoo Finance
Viking Therapeutics Starts Mid-Stage Study on Oral Weight-Loss Drug - MSN
Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled. - MSN
Health Care Down as Traders Seek Out Defensive Sectors -- Health Care Roundup -March 14, 2025 at 05:24 pm EDT - Marketscreener.com
Why Viking Therapeutics Inc. (VKTX) Is Skyrocketing Today? - MSN
Viking Therapeutics, Inc. (VKTX) Ascends While Market Falls: Some Facts to Note - MSN
Viking Therapeutics: No Buyout Needed Now (NASDAQ:VKTX) - Seeking Alpha
(VKTX) Long Term Investment Analysis - Stock Traders Daily
How to Play VKTX Stock Amid Manufacturing Deal With CordenPharma - Zacks Investment Research
Viking Therapeutics (NASDAQ:VKTX) Earns “Buy” Rating from HC Wainwright - Defense World
10 Stocks Skyrocketing Today - Insider Monkey
Why VKTX Stock is Moving Today - GuruFocus.com
Viking Therapeutics Secures Manufacturing Agreement with CordenPharma, Boosting Growth Prospects and Investor Appeal - TipRanks
Why Viking Therapeutics and Roche Holdings Popped Today, but Novo Nordisk Stock Dropped - Yahoo
Viking Therapeutics’ new contract is a game changer. Here’s how much money it could bring in. - MarketWatch
Behind the Scenes of Viking Therapeutics's Latest Options Trends - Benzinga
B. Riley sees two key positives in Viking manufacturing agreement - Yahoo Finance
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking shares slip after manufacturing deal announced - The Pharma Letter
VKTX Inks Manufacturing Deal With CordenPharma for Obesity Drug Supply - Yahoo Finance
Viking Therapeutics Is Ready For A Standalone Future (NASDAQ:VKTX) - Seeking Alpha
Viking Therapeutics Secures Strategic Manufacturing Agreement with CordenPharma, Boosting Growth Potential and Earning Buy Rating - TipRanks
Viking Therapeutics Secures Strategic Manufacturing Agreement, Boosting Investor Confidence and Phase 3 Trial Prospects - TipRanks
Bank of New York Mellon Corp Grows Position in Viking Therapeutics, Inc. (NASDAQ:VKTX) - Defense World
CordenPharma and Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables and Oral Formulations - Barchart
Health Care Down on Flight From Biotech, Obesity Drug Makers -- Health Care Roundup - Marketscreener.com
Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 - The Malaysian Reserve
Viking Therapeutics: Finally, Here Comes The Buying Opportunity (Upgrade) - Seeking Alpha
Stellantis, Tesla, Viking Therapeutics: Market Minute - Yahoo Finance
Viking Therapeutics closer to bringing its Ozempic competitor to market - Yahoo Finance
Viking Therapeutics Shares Fall After Manufacturing Deal With CordenPharma -March 11, 2025 at 11:08 am EDT - Marketscreener.com
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.05%
1.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):